Yarrow Bioscience Q3 2026 Results: Net Loss of $9.72M
Yarrow Bioscience, Inc. reported a net loss of $9.7 million for the third quarter of 2026, driven by $10.7 million in operating expenses. Following a merger, the company significantly strengthened its balance sheet, ending the period with $268.9 million in cash and cash equivalents compared to $100.0 million at the end of 2025.
- Key figure
- Net loss $9.72M